Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Cerilliant
Argus Health
Baxter
Fish and Richardson
Chubb
Medtronic
Federal Trade Commission
Julphar

Generated: May 27, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,241,910

« Back to Dashboard

Summary for Patent: 9,241,910
Title:Orally-disintegrating solid preparation
Abstract: The present invention provides an orally-disintegrating solid preparation such as a tablet produced by tabletting fine granules showing controlled release of a pharmaceutically active ingredient and an additive, and the like, and the orally-disintegrating solid preparation containing fine granules coated with a coating layer containing a polymer affording a casting film having an elongation at break of about 100-about 700%. With the preparation, breakage of fine granules during tabletting can be suppressed in the production of an orally-disintegrating solid preparation containing fine granules showing controlled release of a pharmaceutically active ingredient.
Inventor(s): Kurasawa; Takashi (Osaka, JP), Watanabe; Yasuko (Osaka, JP), Omachi; Yoshihiro (Osaka, JP)
Assignee: Takeda Pharmaceutical Company Limited (Osaka, JP)
Application Number:12/921,731
Patent Claim Types:
see list of patent claims
Formulation; Compound; Dosage form; Delivery;

Drugs Protected by US Patent 9,241,910

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Takeda Pharms Usa DEXILANT SOLUTAB dexlansoprazole TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL 208056-001 Jan 26, 2016 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 9,241,910

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2008-061673Mar 11, 2008
Japan2008-334920Dec 26, 2008
PCT Information
PCT FiledMarch 10, 2009PCT Application Number:PCT/JP2009/054983
PCT Publication Date:September 17, 2009PCT Publication Number: WO2009/113703

International Family Members for US Patent 9,241,910

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Ukraine 105628 ➤ Try a Free Trial
Taiwan I441658 ➤ Try a Free Trial
Taiwan 200944249 ➤ Try a Free Trial
Tunisia 2010000411 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Farmers Insurance
Mallinckrodt
McKinsey
Chinese Patent Office
Julphar
Daiichi Sankyo
Argus Health
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.